OncoMatch/Clinical Trials/NCT05451043
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Is NCT05451043 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for pancreatic cancer.
Treatment: Durvalumab · Gemcitabine · Nab paclitaxel · Tremelimumab · Propranolol · Cisplatin — A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol 1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients. 2. HCC Durvalumab will be administered once every 4 weeks in combination with continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients. 3. Biliary Tract Cancer (BTC, Cholangiocarcinoma of the gallbladder or bile ducts) Durvalumab will be administered once every 3 weeks, in combination with cisplatin + gemcitabine (day 1/8) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Hepatocellular Carcinoma
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Exception: palliative systemic treatment for advanced cancer
Patients who have received prior palliative systemic treatment for their advanced cancer.
Cannot have received: durvalumab and/or tremelimumab
Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) >1.5 x10^9/L; Platelet count >100 x10^9/L (>65 x10^9/L for HCC cohort); Hemoglobin >9 g/dL (may have been transfused)
Kidney function
Estimated creatinine clearance ≥ 45 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
Liver function
Total serum bilirubin <1.5x ULN (≤2x ULN for HCC cohort); AST and ALT <2.5x ULN (≤5x ULN for patients with documented metastatic disease to the liver)
The following adequate organ function laboratory values must be met: Hematological: Absolute neutrophil count (ANC) >1.5 x109/L; Platelet count >100 x109/L (>/ 65 x109/L for HCC cohort); Hemoglobin >9 g/dL (may have been transfused). Renal: Estimated creatinine clearance ≥ 45 mL/min according to the Cockcroft-Gault formula (or local institutional standard method). Hepatic: Total serum bilirubin <1.5x ULN (≤2x ULN for HCC cohort); AST and ALT <2.5x ULN (≤5x ULN for patients with documented metastatic disease to the liver)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify